[
    [
        {
            "time": "2018-03-15",
            "original_text": "Do the Risks in Marijuana Stocks Outweigh the Rewards?",
            "features": {
                "keywords": [
                    "Risks",
                    "Marijuana Stocks",
                    "Outweigh",
                    "Rewards"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Do the Risks in Marijuana Stocks Outweigh the Rewards?",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus",
            "features": {
                "keywords": [
                    "Pharma Stock",
                    "Approval",
                    "NVS",
                    "ABBV",
                    "Cancer Drugs",
                    "MRK",
                    "HIV Drug"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus",
            "features": {
                "keywords": [
                    "Pharma Stock",
                    "Approval",
                    "NVS",
                    "ABBV",
                    "Cancer Drugs",
                    "MRK",
                    "HIV Drug"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline",
            "features": {
                "keywords": [
                    "Large Cap",
                    "Pharma Stocks",
                    "Focus",
                    "Robust",
                    "Cancer Pipeline"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]